University of California San Francisco
San Francisco, California, United States
Purpose
to use a novel animal model to determine the relative attenuation phenotype or immunogenicity of new oral polio vaccine (OPV) viruses including those made by the consortium for a new OPV-2 as benchmarked against virus Sabin-2
Division
Global Development, Global Health
Date
October 2013
Region Served
GLOBAL
Committed amount
$1,582,628
Grant topic
Create Novel Technology Platform Capabilities, Polio, Vaccine Development
Duration (months)
98
Grantee location
San Francisco, California, United States
More about our financials
Our story
Learn about the origins of the foundation and the values that drive our work.
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.